Balance Sheet
Cash Flow Statement
AcquisitionsAmortization of Deferred ChargesAmortization of Deferred ChargesAmortizatization of IntangiblesAmortizatization of IntangiblesAsset Writedowns and ImpairmentAsset Writedowns and ImpairmentCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in CashChange in IntangiblesChange in IntangiblesChange in InventoryChange in InventoryChange in ReceivablesChange in ReceivablesChange in TaxesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionDividends Paid - CommonDividends Paid - CommonExchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesLong-Term Debt IssuancesNet Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesOther Working Capital ChangesOther financing activitiesOther financing activitiesShare-based CompensationShare-based CompensationShares IssuedShares RepurchasedShort-Term Debt repayments
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ani Pharmaceuticals (ANIP) Gains from Sales and Divestitures (2017 - 2023)

Ani Pharmaceuticals (ANIP) has disclosed Gains from Sales and Divestitures for 7 consecutive years, with $235000.0 as the latest value for Q1 2023.

  • Quarterly Gains from Sales and Divestitures rose 45.96% to $235000.0 in Q1 2023 from the year-ago period, while the trailing twelve-month figure was $235000.0 through Mar 2023, up 45.96% year-over-year, with the annual reading at $245000.0 for FY2022, 96.0% up from the prior year.
  • Gains from Sales and Divestitures hit $235000.0 in Q1 2023 for Ani Pharmaceuticals, down from $245000.0 in the prior quarter.
  • In the past five years, Gains from Sales and Divestitures ranged from a high of $245000.0 in Q4 2022 to a low of $34000.0 in Q1 2021.
  • Historically, Gains from Sales and Divestitures has averaged $126937.5 across 5 years, with a median of $125500.0 in 2021.
  • Biggest five-year swings in Gains from Sales and Divestitures: plummeted 30.61% in 2021 and later surged 373.53% in 2022.
  • Year by year, Gains from Sales and Divestitures stood at $42000.0 in 2019, then surged by 202.38% to $127000.0 in 2020, then fell by 1.57% to $125000.0 in 2021, then skyrocketed by 96.0% to $245000.0 in 2022, then decreased by 4.08% to $235000.0 in 2023.
  • Business Quant data shows Gains from Sales and Divestitures for ANIP at $235000.0 in Q1 2023, $245000.0 in Q4 2022, and $234000.0 in Q3 2022.